# A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

> **NCT00442611** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 10 (actual)

## Conditions studied

- Scleroderma, Diffuse
- Scleroderma, Systemic

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00442611
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442611, "A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00442611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*